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HEALTH CARE USE & POLICY STUDIES – Disease Management
PHP6
ROUTINE OF PATIENTS’ REDIRECTION IN THE HUNGARIAN PRIMARY 
CARE
Lipp S1, Boncz I2, Gresz M3, Varga S2, Oláh A2, Marada G2, Sebestyén A1
1National Health Insurance Fund Administration, Pécs, Hungary; 2University of Pécs, Pécs, 
Hungary; 3National Health Insurance Fund Administration, Budapest, Hungary
OBJECTIVES: The aim of this study is to analyze the GPs’ routine of redirection. We 
reveals which diagnoses induce the most frequent redirection cases to specialists, which 
specialties are the most frequently targeted and how the distance from the nearest 
outpatient unit inﬂ uences the GPs’ practice. METHODS: The analysis is based on the 
monthly reports (B300 form of the Hungarian Naional Health Insurance Fund Admin-
istration (OEP) of 701 general practitioners. Study covers the years 2008 and 2009, 
14 million visits of 952 thousand inhabitants of South-Transdanubian Region of 
Hungary. GPs’ redirection routine is measured by the redirection rate, which shows 
the number of redirections related to the number of GP visits (%). RESULTS: The 
population of the region decreased by 0.8% over the years 2008–2009, however the 
number of GP visits increased by 12%. The surplus is mainly due to the H1N1 vac-
cination campaign and the rise of cardiovascular diseases and respiratory diseases of 
allergic origin. The average redirection rate was 10%. 76% of the GPs’ surgeries are 
located not farther than 15 km from the nearest outpatient unit, and 62% not farther 
than 15 km from a hospital. The distance from the nearest outpatient unit inﬂ uences 
the redirection rate, but this impact is not determining. The most frequently needed 
specialties are rheumatology, cardiology, pulmonology and orthopedics. GPs direct 
their patients of 0–14 years to specialists more rarely than patients of 15 years or 
above and also the referred diagnoses vary between the two age groups. CONCLU-
SIONS: The redirection rate is lower on case of young patients and higher on case of 
adult, and elderly patients. While young patients get to specialists mainly due to acute 
and chronic respiratory diseases (many of them have allergic origin), orthopaedic 
malformations or simply health monitoring, adult patients have cardiovascular, rheu-
matic, and endocrine problems.
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AN EXPLORATORY STUDY EVALUATING THE PREPAREDNESS OF 
PRACTICING COMMUNITY PHARMACISTS IN MALAYSIA FOR 
MANAGEMENT ROLES
Al-Haddad M, Hassali MA
Universiti Sains Malaysia, Penang, Malaysia
OBJECTIVES: To evaluate the preparedness of the community pharmacists in the 
State of Penang in six main management functions: Accounting, ﬁ nance, human 
resource management, marketing management, planning, and directing. METHODS: 
A cross-sectional study design was carried out with a total of 100 community phar-
macists practicing in the State of Penang, Malaysia. a pre-validated questionnaire, 
containing 3 sections was used as data collection tool. All data was analyzed using 
SPSS for Windows version 13.0. Inferential statistics were used whenever appropriate 
at alpha value of 0.05 or less considered signiﬁ cant. RESULTS: A total of 50 phar-
macists successfully responded to the survey. When respondents were asked about the 
percentage of time spent in actual management functions, 42% of them responded 
that their time is being spent on actual management functions. More than 60% of 
community pharmacists said that most of the time, they undertake tasks in accounting, 
ﬁ nance, human resource management, marketing management, planning, and direct-
ing. When respondents were compared in terms of their demographics, the time 
overseas graduates showed better preparation and performance of management func-
tions compared to local graduates. CONCLUSIONS: The ﬁ ndings of this study 
showed that most of the community pharmacists understand and undertake the 
management functions in running their community pharmacy business. Furthermore 
the ﬁ ndings suggested that local pharmacy graduates were less prepared to undertake 
various management functions compared to their overseas graduated counterparts.
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INTERVENTIONS TO REDUCE HOSPITAL READMISSIONS IN THE 
ELDERLY
Linertová R1, García-Pérez L1, Vázquez-Díaz JR2, Lorenzo-Riera A3, Sarría-Santamera A4
1Fundación Canaria de Investigación y Salud (FUNCIS), Las Palmas de Gran Canaria, Spain; 
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OBJECTIVES: Unplanned hospital readmissions of elderly people present an increas-
ing burden for health systems. This could be, theoretically, reduced by adequate 
preventive interventions. However, there is uncertainty about the effectiveness of dif-
ferent types of interventions. The objective of this systematic review was to summarise 
available evidence on the effectiveness of interventions to reduce the risk of unplanned 
readmissions in patients of 75 years and older and to determine the role of home care 
components. METHODS: We searched studies in MEDLINE, CINAHL, CENTRAL 
and seven other electronic databases up to October 2007 and updated the search in 
MEDLINE up to October 2009. Clinical trials (randomized or controlled) evaluating 
the effectiveness of an intervention to reduce readmissions in elderly patients compared 
to a control group were selected. Quality was assessed by the SIGN tool. The extracted 
information was presented in text and tables. RESULTS: Thirty-two clinical trials 
were included and divided into two groups: in-hospital interventions (17 studies) and 
interventions with home follow-up (15 studies). Three studies from the ﬁ rst group and 
seven from the second group found positive effects of the evaluated intervention on 
readmission outcome. CONCLUSIONS: Most of the evaluated interventions did not 
have any effect on readmissions of elderly patients. However, those interventions that 
comprised some kind of home care seem to be more likely to reduce readmissions in 
the elderly. 
HEALTH CARE USE & POLICY STUDIES – Drug/Device/Diagnostic Use & 
Policy
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BUDGET IMPACT ANALYSIS OF ORPHAN DRUGS IN BELGIUM: 
ESTIMATES FROM 2008 TO 2013
Denis A1, Mergaert L1, Fostier C1, Cleemput I2, Simoens S3
1Yellow Window Management Consultants, Antwerp, Belgium; 2Belgian Health Care 
Knowledge Centre, Brussels, Belgium; 3K.U. Leuven, Leuven, Belgium
OBJECTIVES: This study aims to calculate the impact of orphan drugs on the Belgian 
drug budget in 2008 and to forecast its impact over the following ﬁ ve years. 
METHODS: The 2008 budget impact was calculated by triangulating information 
derived from multiple Belgian data sources, including Ministerial Decrees, ﬁ gures 
published by the National Institute for Health and Disability Insurance, and reim-
bursement ﬁ les submitted to the Drug Reimbursement Committee. The 2008–2013 
budget impact analysis was based on three scenarios reﬂ ecting different levels of 
growth in the number of registered orphan drugs in the European Union, the number 
of drugs reimbursed in Belgium, and the average annual cost per patient per drug in 
Belgium. The price year was 2008. RESULTS: At the end of 2008, 31 different orphan 
drugs were approved for reimbursement in Belgium for 35 different indications. The 
annual number of Belgian patients treated varied between 1 and 1080 patients per 
orphan drug. The cost per patient per year ranged from c4600 to c411,000 between 
orphan drugs. The orphan drug budget impact amounted to c66.2 million (or 5% of 
the Belgian hospital drug budget) in 2008. The impact would increase to c130–c204 
million in 2013, depending on the scenario. CONCLUSIONS: The analysis showed 
that the budget impact of orphan drugs in Belgium is substantial and rising, thereby 
putting pressure on total drug expenditure. This static analysis measured orphan drug 
costs only, assuming that other components of health expenditure do not change over 
time. Policy options to address the rising budget impact include pricing linked to return 
on investment, risk-sharing arrangements and re-appraisal of orphan drug status if 
additional indications are approved.
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DOES THE MARKET SHARE OF GENERIC MEDICINES INFLUENCE THE 
PRICE LEVEL? A EUROPEAN ANALYSIS
Dylst P, Simoens S
K.U. Leuven, Leuven, Belgium
OBJECTIVES: This study aims to investigate the relationship between the market 
share of generic medicines and the medicine price level in European off-patent phar-
maceutical markets. METHODS: Data on medicine volumes and on medicine values 
for a basket of 35 active substances were derived from IMS Health. Ex-manufacturer 
medicine prices were calculated by dividing market value by market volume. The 
analysis was limited to medicines in immediate-release, oral, solid dosage forms. The 
included countries were Austria, Belgium, Denmark, Germany, France, Italy, the The 
Netherlands, Spain, Sweden and the United Kingdom, which constitute a mix of 
countries with low and high generic medicines market shares. Data were available 
from June 2002 until March 2007. RESULTS: Market value has seen a substantial 
decrease in high generic market share markets (−26.6%), while the decrease in low 
market share markets was marginal (−0.06%). Market volume has risen in both high 
generic market share markets (+29.27%) and low market share markets (+27.40%) 
but the cause of rise is different for the two markets. In low generic market share 
markets, the rise was caused by the increased use of generic medicines while in high 
market share markets the rise was driven by the increased use of generic medicines 
and a shift of use from originator to generic medicines. In high generic market share 
markets, medicines prices have dropped by −43.18% and in low market share markets 
by −21.56%. CONCLUSIONS: The extent to which price competition from generic 
medicines leads to price reductions appears to vary according to the market share of 
generic medicines. High market share markets of generic medicines have seen a larger 
decrease in medicine prices than low market share markets. Countries need thus to 
create an environment which stimulates the generic medicines use and so increases the 
market share.
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NEW AND IMPROVED: DEFINING INNOVATION FOR HEALTH 
TECHNOLOGY POLICY
Davis C, Menon D
University of Alberta, Edmonton, AB, Canada
OBJECTIVES: Both individuals and society stand to beneﬁ t from encouraging health 
technological innovation—individual patients through quicker access to promising 
technologies, and society through the development of a competitive life sciences sector. 
The “Innovation Pass” (UK) and the “Critical Path Initiative” (US) are 2 examples of 
current health policies aimed at promoting innovation. However, there does not seem 
to be a clear agreement on what constitutes innovation. The objective of this project 
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was to identify existing deﬁ nitions of innovation, values inherent in innovation initia-
tives, and important considerations for the development of policies to promote innova-
tion of health technologies. METHODS: A literature search of bibliographic databases 
including PubMed, EMBASE, Web of Science, Centre for Reviews and Dissemination 
databases, National Library of Medicine Gateway, EconLit and the New York 
Academy of Medicine Grey Literature collection was conducted for the period January 
2005 to April 2010. The search terms were intended to capture concepts of “innova-
tion” and “policy” in the health technology (drugs, devices, etc,) sector. Two research-
ers reviewed titles and abstracts of over 4500 references identiﬁ ed; 200 papers were 
retrieved for full review. Key components of innovation were extracted and summa-
rized in tabular form to identify trends and emerging themes. RESULTS: System 
disrupting, development of relationships and improvement on current practice are 
examples of components of, or criteria for deﬁ ning, health technology innovation. 
Thematic concepts that emerged during the review include innovative health technol-
ogy as a novelty and as a mechanism for achieving some beneﬁ t or good (broadly-
deﬁ ned) at various levels of the health system. CONCLUSIONS: Based on the variety 
of deﬁ nitions in the literature, lack of a common understanding of innovation may 
result in policy incoherence. The use of a consistent and unambiguous deﬁ nition 
provides a solid framework from which to develop policy that is measurable, meaning-
ful and, therefore, has a greater chance of being effective.
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PHYSICIANS VIEWS ON BIOMEDICAL TECHNOLOGY IN GREECE
Tsiantou V1, Skroumpelos A1, Mylona K1, Athanasakis K1, Konstantinopoulos O2, 
Kyriopoulos J1
1National School of Public Health, Athens, Greece; 2Sotiria Hospital, Athens, Greece
OBJECTIVES: Given the signiﬁ cant impact of biomedical technology on health, the 
present study aims at identifying the accessibility to certain biomedical technologies 
and factors affecting its use and diffusion, in Greece. METHODS: A strictly structured 
questionnaire was designed and sent to a sample of 388 internists and GPs over 50 
years old, stratiﬁ ed by geographical area and employment sector. Participants were 
asked a) to evaluate on a 1 to 10 point scale patient access to selected biomedical 
technologies and the degree to which selected factors affect their decision to use the 
above interventions and b) to rank certain factors effect on the diffusion of biomedical 
technologies. RESULTS: The response rate was 76%. The statistical analysis revealed 
that the most accessible biomedical technologies were ultrasonography (9.4), PSA 
(9.38), cardiac enzymes (8.99), MRI and CT (8.86), and mammography (8.83). The 
most important factors affecting participants’ decision to use a technology were the 
treatment outcome (9.23), the disease severity (9.11) and the appropriateness of the 
technology for each condition (8.27) while factors such as health system and patient 
cost were proved less inﬂ uential. 68.1% of participants claimed delays in the diffusion 
of biomedical technology in Greece, identifying as major barriers economic and spe-
cialized human resources deﬁ ciencies. CONCLUSIONS: Based on our results, higher 
access was observed to technologies related to neoplasms and cardiovascular diseases, 
which represent the main causes of morbidity and mortality in Greece. Furthermore, 
our ﬁ ndings support the view that when it comes to use a technology physicians are 
mostly concerned with the clinical effectiveness of an intervention and less with its 
impact on health care expenditures. Finally, the major diffusion barriers identiﬁ ed in 
this study show a suboptimal resource allocation practice, stressing the need for 
measures to be taken in this direction in order to enhance diffusion of biomedical 
technologies in Greece.
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IMPLEMENTATION OF THE TRANSPARENCY DIRECTIVE IN HUNGARY
Kalo Z1, Nagyjanosi L2
1Eötvös Loránd University, Budapest, Hungary; 2Syreon Research Institute, Budapest, Hungary
OBJECTIVES: Transparency Directive (TD) of the European Union aims to ensure 
the transparency of procedures for the pricing and reimbursement of medicinal prod-
ucts by Member States. TD proposes strict timelines for the pricing and reimbursement 
process and indicates the necessity of objective and veriﬁ able criteria for decisions and 
the availability of remedies for negative decisions. Our objective was to compare the 
routine process of pharmaceutical pricing and reimbursement with the TD in Hungary. 
METHODS: We analyzed ofﬁ cial resolutions of 29 pricing and reimbursement sub-
missions by the National Health Insurance Fund (NHIF) between January and June 
2008. In 14 cases the NHIF granted reimbursement, in 15 cases the reimbursement 
claim was rejected. We calculated the time period between the submission of the 
reimbursement dossier and the ofﬁ cial decision. We assessed the consistency of apply-
ing objective and veriﬁ able criteria in positive or negative decisions. RESULTS: The 
average time period for pricing and reimbursement procedure was 172 days (min: 43 
days; max: 534 days). We could not justify the consistency of employing objective and 
veriﬁ able criteria in the pricing and reimbursement resolutions of innovative pharma-
ceuticals. CONCLUSIONS: The pharmaceutical pricing and reimbursement process 
in Hungary is neither transparent nor predictable. There are several open pricing and 
reimbursement submissions without resolution for long period. Although we could 
analyze only cases with resolution, the time period for pricing and reimbursment 
decision was still longer in several cases than 90 + 90 days recommended by TD. The 
appropriate use of scarce public health care resources could not be justiﬁ ed in case of 
positive decisions and there is no remedy for negative reimbursement decisions. TD 
has been implemented only partially in Hungary.
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THE JOINT COMMITTEE FOR NEW DRUGS EVALUATION IN SPAIN: 6 
YEARS OF EXPERIENCE
Collar J
Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
OBJECTIVES: The Joint Committee for New Drugs Evaluation (JCNDE) was estab-
lished in 2003 to improve efﬁ ciency in drug evaluation in Spain. Five Regional Drug 
Evaluation Centres are part of it and have common Standard Operating Procedures 
(SOPs) which are regularly updated and improved. The objective of this study was to 
analyze the drugs innovation degree scores assigned by the JCNDE and timing between 
the new drug commercialization and the JCNDE evaluation. METHODS: The JCNDE 
SOPs deﬁ ne a stepwise procedure with 4 key criteria for new drug innovation ratings: 
efﬁ cacy, safety, convenience and drug cost. The drug innovation scores range from 0 
(insufﬁ cient experience with the drug) to 4 (relevant therapeutic improvement). The 
drug evaluation results were gathered from JCNDE reports and from the Regional 
Drug evaluation centre reports. The time period analyzed was from 2004 to 2009. 
RESULTS: Ninety drug evaluations were held, considering 86 different drugs and 11 
evaluations for a new drug indication for the same drug. Seventy-eight (87%) of the 
evaluations were negative (scores 0–1), not ﬁ nding any 0 in the last 2 years of the 
study. Ten and 2 evaluations were scored as 2 and 3 respectively. None of the drugs 
assessed were considered a relevant therapeutic improvement compared to the existing 
options. Five drugs not reimbursed were evaluated. Median time since commercializa-
tion to evaluation was 6 months (IQR: 2–11 months) and 32 drug evaluations were 
held before up to a maximum of 3 months after commercialization. CONCLUSIONS: 
The JCNDE has been an efﬁ cient instrument to develop new drug assessments in the 
Primary Care setting for the Regional Health Systems in Spain. Most of the assess-
ments held have been negative. At present, health-economics arguments are basically 
focused on the daily treatment cost comparisons. About 1/3 of the evaluations are 
started before drug commercialization.
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DRUG COMPARATOR DIFFERENCES IN THE THERAPEUTIC BULLETINS 
IN SPAIN: THE JCNDE EXPERIENCE
Collar J
Pharmacoeconomics & Outcomes Research Iberia, Madrid, Spain
OBJECTIVES: The Spanish Joint Committee for New Drugs Evaluation (JCNDE) was 
created in 2003 and is formed by 5 Regional Drug Evaluation Centres. JCNDE has 
common Standard Operating Procedures (SOPs) to unify drug assessments and where 
the comparators availability is a key issue. Each individual Drug Evaluation Centre 
has its own new drug therapeutic bulletin to spread information between their health 
professionals. The objective of this study was to quantify the uniformity degree 
through the drug bulletins and the degree of heterogeneity reﬂ ected in the drug costs. 
METHODS: New drug therapeutic bulletins of the 5 members of the JCNDE were 
reviewed between 2006 and 2009. Each drug assessed by the JCNDE was tracked to 
identify which members reported it in their bulletins. Comparative drugs included in 
the bulletins were also registered to ﬁ nd potential heterogeneity amongst the JCNDE 
members. Daily/monthly treatment costs described were included in the study data-
base. RESULTS: Fifty-seven drug evaluations were recorded, forty (70%) were pub-
lished by at least 3 members of the JCNDE, and only 12 were published by all of 
them. Andalusia, Basque Country and Catalonia are the most active members, with 
12–14 new drugs published per year. In all the bulletins were identiﬁ ed some differ-
ences in the comparators used for each new drug assessed. Andalusia and Catalonia 
tend to include more comparators. The highest level of heterogeneity is observed in 
drugs of diabetes treatment. Most of the drug costs reported were very similar. Only 
one disagrement between the JCNDE was identiﬁ ed in the drug innovation rating. 
CONCLUSIONS: JCNDE has made advances to unify drug assessment in Spain. 
Nevertheless, health-economics arguments are still focused on drug treatment cost 
comparisons. The comparators found in the drug bulletins are slightly different 
amongst the regions. Future SOPs version ought to improve these two weak points.
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ACCESSIBILITY TO ORPHAN DRUGS IN JAPAN—HAS THE ORPHAN 
DESIGNATION SYSTEM CONTRIBUTED?
Tomita N1, Kodama T2, Inagaki A1
1Keio University, Kanagawa, Japan; 2National Institute of Public Health, Saitama, Japan
OBJECTIVES: To promote the research and development of drugs for rare diseases, 
like other countries, orphan designations have been granted to pharmaceuticals in 
Japan since 1993. We investigated the accessibility of orphan drugs in Japan by 
comparing the accessibility of orphan designated and marketing authorised drugs in 
the EU and the US. METHODS: The present study used the data available until the 
November 30, 2009 from the European Medicines Agency, US Food and Drug 
Administration and National Institute of Biomedical Innovation. The International 
Nonproprietary Names (INNs) were used for comparing authorised orphan desig-
nated drugs in Japan, the EU and the US. RESULTS: A total of 228 products had 
been granted orphan designation, of which 142 (62%) obtained marketing authoriza-
tion in Japan, which is equivalent to 122 in INNs. Meanwhile, the number of autho-
rised orphan-designated medicines in INNs in the EU and the US was 57 and 198, 
respectively. Of the total 287 authorised orphan-designated pharmaceuticals in INNs 
in these 3 regions, 165 were inaccessible in Japan through the orphan designation 
system. Among such drugs, 25 (15%) were authorised orphan designated in both the 
EU and the US, 15 (9%) were authorised orphan designated in the EU alone and 125 
(76%) were authorised orphan designated in the US alone. CONCLUSIONS: We 
